A phase 1 open-label single-radiolabeled dose study to investigate the absorption, metabolism and excretion of [14C] PD 0332334 [PD-332334] in six healthy male volunteers.
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2010
At a glance
- Drugs Imagabalin (Primary)
- Indications Generalised anxiety disorder
- Focus Pharmacokinetics
- Sponsors Pfizer
- 02 Nov 2008 Actual patient number (6) added as reported by ClinicalTrials.gov.
- 21 Jan 2008 Status changed from initiated to completed as reported by ClinicalTrials.gov.
- 16 Oct 2007 New trial record.